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Background: The pathogenicity of many Mendelian variants has been challenged by large-scale sequencing efforts.
However, many rare and benign “disease mutations” are difficult to analyze due to their rarity. The Saudi Arabian
variome is enriched for homozygosity due to inbreeding, a key advantage that can be exploited for the critical
examination of previously published variants.
Results: We collated all “disease-related mutations” listed in the Human Gene Mutation Database (HGMD) and
ClinVar, including “variants of uncertain significance” (VOUS). We find that the use of public databases including
1000 Genomes, ExAC, and Kaviar can reclassify many of these variants as likely benign. Our Saudi Human Genome
Program (SHGP) can reclassify many variants that are rare in public databases. Furthermore, SGPD allows us to
observe many previously reported variants in the homozygous state and our extensive phenotyping of participants
makes it possible to demonstrate the lack of phenotype for these variants, thus challenging their pathogenicity
despite their rarity. We also find that 18 VOUS BRCA1 and BRCA2 variants that are listed in BRCA Exchange are
present at least once in the homozygous state in patients who lack features of Fanconi anemia. Reassuringly, we
could reciprocally demonstrate that none of those labeled as “pathogenic” were observed in the homozygous
statue in individuals who lack Fanconi phenotype in our database.
Conclusion: Our study shows the importance of revisiting disease-related databases using public resources as well
as of population-specific resources to improve the specificity of the morbid genome of Mendelian diseases in
humans.
Keywords: Saudi Human Genome Program (SHGP), Autozygosity, Variant classification, Disease mutationsBackground
DNA variation in human populations express itself
phenotypically in an extremely broad spectrum ranging
from embryonic lethality to complete lack of phenotypes
[1–5]. An added layer of complexity lies in the effect size
of the variants, which again displays a wide range from
the infinitesimal to the fully penetrant. Historically,
study of DNA variants has focused on those that are
highly penetrant with a recognizable clinical conse-
quence, so-called Mendelian variants [6]. Despite the re-
cent explosion in our knowledge of how variants can
influence risk for many common diseases, Mendelian
variants remain the most clinically actionable, with most
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class of variants [6].
Unlike most laboratory tests in the clinical setting,
medical DNA sequencing is qualitative in nature and re-
quires extensive assessment of each variant prior to
reporting. Until recently, there were no standard guide-
lines for establishing disease-variant links. The com-
monly held view that truncating variants are pathogenic
was first challenged by the finding that many single nu-
cleotide polymorphisms (SNPs) are truncating in nature
and this was further confirmed by large-scale sequencing
studies [1, 7–10]. Similarly, the practice of screening 100
individuals of a similar ethnicity to confirm pathogen-
icity of a given allele suffered the fallacy of the 1% fre-
quency definition of SNPs, which is now seen as
arbitrary since there are many rare, ultra-rare, or even
private SNPs that do not cause any Mendelian disease.
This has resulted in the publication of numerousle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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databases as “disease mutations” with little evidence of
pathogenicity [11, 12].
The recent American College of Medical Genetics and
Genomics (ACMG) guidelines on the interpretation of
variants provide the much-needed standardization of
reporting variants, although labs continue to have con-
flicting interpretation even when using these guidelines
[13, 14]. Key in these guidelines is the emphasis on allele
frequency and segregation with the phenotype [14].
Alleles with a frequency that is too high for the disease
in question and those that do not segregate with the
phenotype should be classified as benign, the issue of re-
duced penetrance notwithstanding. Indeed, many “dis-
ease mutations” were subsequently found to be benign
using large-scale sequencing efforts [12]. Similarly, the
increasingly common use of clinical genomics has re-
vealed many “disease mutations” that clearly do not seg-
regate with the disease, although efforts to make such
valuable findings publicly available remain limited [15].
In this study, we hypothesized that there are false “dis-
ease mutations” whose frequency in 1000 Genome,
Kaviar, and ExAC is low but are in fact common variants
among Saudi Arabians, an ethnicity with poor represen-
tation in the aforementioned variant databases and para-
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Reclassified variants based on our four exclusion criteria for the HGMD and ClinVar
variants filtered by 1000 Genomes, then by ExAc, then by Kaviaron positional mapping studies. We also hypothesized
that the high degree of inbreeding among Saudi
Arabians will render homozygous at least some “disease
mutations” in individuals who lack the phenotype. In
both instances, large-scale sequencing of Saudi Arabians
should permit the reclassification of many alleles as
benign, which is otherwise not possible using 1000
Genomes, Kaviar, and ExAC, as we demonstrate in this
study.
Results
The morbid genome has specificity limitations
As of August 2016, there are 187,319 variants listed in
HGMD related to “disease mutations” (Classes, DM,
“DM?”), mostly missense (76%). The corresponding
ClinVar list comprises 82,543 variants, including 37,345
pathogenic, 7914 likely pathogenic, and 37,284 VOUS,
mostly missense (86%).
Table 1 summarizes the results of reclassifying the var-
iants in the Human Gene Mutation Database (HGMD)
and ClinVar based on the four criteria described in
“Methods” (all reclassified variants are included in the
supplemental tables). The number of HGMD disease-
related mutations, including classes DM and DM?, that
can be classified as benign based on population fre-























databases. The numbers between brackets for Criteria 1 are for the number of
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“Methods”) was 255 at an allele frequency threshold of
5% (Additional file 1: Table S1).
As expected based on its more recent development, its
reliance on large public variant databases, and more
stringent scoring system, the number of variants listed
by ClinVar that could be classified as benign was much
smaller: 122 pathogenic and 18 likely pathogenic at an
allele frequency threshold of 5% (Additional file 2:
Table S2). Similarly, the number of ClinVar VOUS that
can be reclassified as benign based on 1000 Genomes,
Kaviar, or ExAC was 194 at an allele frequency threshold
of 5% (Additional file 2: Table S2). Reassuringly, very few
of the “reclassified” variants in ClinVar and HGMD were
truncating in nature (8.0% [7.9% HGMD, 8.1% ClinVar]).
The Saudi Human Genome Program database can
improve the annotation of the human morbid genome
Because many disease genes were first described in Arab
patients given the high rate of consanguinity, which
facilitates positional mapping, and because this ethnicity
is underrepresented in publicly available variant data-
bases, we expected that at least some published “disease
variants” may represent Arab-specific or Arab-enriched
common variants that cannot be identified as such using
these databases. On the other hand, the Saudi Human
Genome Program (SHGP) database, which represents
the largest database of genetic variants from individuals
of Arab ethnicity, should uncover such Arab-specific
and Arab-enriched common variants. Indeed, our ana-
lysis revealed that 16 variants in HGMD (1 DM and 15
DM?) and 10 in ClinVar (6 Pathogenic, 4 VOUS)
achieved a population frequency of 5% in the SHGP
database but were <5% in public databases so they can
be confidently reclassified as benign (Additional file 3:
Table S3 and Additional file 4: Table S4). Furthermore,
because the SHGP database is enriched for autozygosity,
we were able to reclassify an additional 607 HGMD (103
DM and 504 DM?) variants and 484 ClinVar (184 Patho-
genic, 25 Likely Pathogenic, 275 VOUS) variants as be-
nign based on a population frequency of >1% and their
presence in the homozygous state in individuals who
lack the reported phenotype (Additional file 5: Table S5
and Additional file 6: Table S6). A special scenario was
frequently encountered when an allele only met the BS2
criterion of the ACMG guidelines (i.e. presence in
homozygosity in disease-free individuals) but not BS1
(i.e. frequency too high for the known disease fre-
quency). Such variants cannot be reclassified as benign
or even likely benign without additional lines of evidence
according to the ACMG guidelines. However, we believe
knowledge of the existence of these variants in homozy-
gosity in disease-free individuals can be very informative
in the interpretation of these variants even though theydid not achieve a population frequency of 1%. Therefore,
we opted to designate these alleles as “BS2-only vari-
ants.” As expected by the high level of autozygosity in
the SHGP database, we have encountered 215 HGMD
(107 DM and 108 DM?) and 70 ClinVar (21 Pathogenic,
43 VOUS, 6 Likely Pathogenic) variants in homozygosity
in individuals who lack the reported phenotype and
these are listed as BS2-only variants (Additional file 7:
Table S7 and Additional file 8: Table S8).
The SHGP database and the BRCA challenge
As listed on their website, “The BRCA Challenge of the
Global Alliance for Genomics and Health aims to ad-
vance understanding of the genetic basis of breast cancer
and other cancers by pooling data on BRCA genetic var-
iants from around the world, bringing together informa-
tion on sequence variation, phenotype and scientific
evidence.” After downloading all pathogenic and VOUS
variants listed in their data repository (BRCA Exchange),
we interrogated these variants for frequency in the
SHGP Database and found 16 variants that have MAF >
0.01. Five of these were observed at least once in homo-
zygosity in individuals who lack the Fanconi anemia
phenotype thus can be confidently classified as benign.
On the other hand, we found an additional 13 variants
that did not achieve MAF > 0.01 but were observed once
in homozygosity in the absence of the Fanconi anemia
phenotype and are thus listed as “BS2-only variants”
(Additional file 9: Table S9).
Pathogenicity prediction and loss of function in
reclassified variants
In Table 2, we summarize the number of pathogenic var-
iants for each set of reclassified variants. For each vari-
ant in the supplementary tables, we report the
pathogenicity predictions that were computed using
SIFT, PolyPhen2, MutationTaster, MetaSVM, and
CADD. We note that there are many reclassified vari-
ants that are predicted damaging, which underscores the
cautionary note made by the ACMG guidelines with
respect to how in silico prediction modules should be
incorporated in weighing the evidence for pathogenicity.
Similarly, the prevalence of reclassified variants that ap-
pear to be loss-of-function (LOF) (ranging from 1.4% in
Criteria 4 for ClinVar to 18% in Criteria 1 in HGMD) is
a reminder that an apparently LOF in a known disease
gene is not a sufficient evidence to prove pathogenicity,
which is also highlighted by the ACMG guidelines.
Discussion
The growing application of clinical genomics in the vari-
ous disciplines of medicine has made the need for im-
proved specificity of the medical annotation of the
human genome a more acute problem than ever before.
Table 2 Summary of pathogenicity and LOF of reclassified variants
HGMD
Reclassification criteria Total reclassified Pathogenicity prediction
(SIFT, PolyPhen, MutationTaster, metaSVM, CADD)
LOF
(stop-gain, frameshift, splicing)
Criteria1: > = 0.05
(Additional file 1: Table S1)
255 9, 24, 16, 5, 77 13, 7, 15 (13.3%)
Criteria 2: > = 0.05 in SGP (and < 0.05 in PublicDB)
(Additional file 3: Table S3)
16 5, 3, 8, 5, 12 2, 0, 1 (18%)
Criteria 3: > = 0.01 in SGP (at least 1 hom)
(Additional file 5: Table S5)
607 97, 127, 149, 66, 288 34, 0, 16 (8.2%)
Criteria 4: <0.01, hom in SGP, no association with
disease
(Additional file 7: Table S7)
215 58, 84, 105, 60, 141 7, 0, 5 (5.5%)
Total = 1093
ClinVar
Reclassification criteria Total reclassified Pathogenicity prediction
(SIFT, PolyPhen, MutationTaster, metaSVM, CADD)
LOF
(stop-gain, frameshift, splicing)
Criteria1 > = 0.05
(Additional file 2: Table S2)
334 23, 35, 11, 9, 65 2, 1, 6 (2.7%)
Criteria 2: > = 0.05 in SGP (and < 0.05 in PublicDB)
(Additional file 4: Table S4)
10 1, 2, 4, 1, 6 0, 0, 1 (10%)
Criteria 3: > = 0.01 in SGP (at least 1 hom)
(Additional file 6: Table S6)
484 69, 86, 70, 41, 165 3, 0, 5 (1.65%)
Criteria 4: <0.01, hom in SGP, no association with
disease
(Additional file 8: Table S8)
70 17, 25, 27, 21, 41 1, 0, 0 (1.4%)
Total = 898
For each set of reclassified variants, a summary of the pathogenicity as predicted by different software tools including, SIFT, Polyphen2, MutationTaster, MetaSVM,
and CADD is given. Also a summary of LOF variants, including those with stop-gain, frameshifts, and splicing, is also given
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Mendelian diseases, it is inevitable that clinical genomics
will uncover the carrier status of at least one or more
“pathogenic” variants [16]. Unfortunately, despite the in-
creasing sophistication of bioinformatics tools, their abil-
ity to annotate variants as pathogenic or benign remains
limited. This is clearly reflected by the ACMG guidelines
that rightly place emphasis on empirical evidence rather
than in silico prediction tools, especially the behavior of
the variant in the human genetic pool, i.e. its segregation
with the phenotype and population frequency. As more
genomes are analyzed, the odds of encountering ultra-
rare variants increase and these can be very challenging
to classify given the very limited available data on these
variants in the human population.
We have been exploiting the unique characteristics of
the Saudi population to identify many pathogenic alleles
in known and novel disease genes, thus contributing to
the morbid genome of Mendelian diseases in humans
[17, 18]. However, we show in this study that our popu-
lation can also improve the specificity of the morbid
genome map of human Mendelian diseases [19]. Not
only do we demonstrate that many variants in question
represent Arab-enriched variants, but we also takeadvantage of autozygosity to show that their presence in
homozygosity does not lead to the reported phenotype,
thus establishing two key lines of evidence in support of
their likely benign nature. Although the latter, i.e. homo-
zygosity without a phenotype, is not in itself sufficient to
classify a variant as benign according to the ACMG
guidelines, it does raise legitimate concerns about its
claimed pathogenicity. By providing a full list of these vari-
ants as “BS2-only variants,” we hope the wider genetics
community will find this list helpful as they weigh the evi-
dence in the context in which they are encountered. Al-
though every effort has been made to exclude the
reported disease phenotype in these homozygotes, we
note that issues related to non-penetrance, and atypical or
mild phenotypes, cannot be fully ruled out. Furthermore,
variants that are only expressed phenotypically when in
trans with more severe variants will evade detection by
our method, although we note that these tend to be rare.
Germline predisposition to cancer represents a pecu-
liar class of Mendelian phenotypes. These typically dom-
inant mutations have age-dependent penetrance, which
forms the basis for their use in the primary prevention
of these cancers when coupled with appropriate med-
ical/surgical intervention [20]. On the other hand, this
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presence in the “controls” cannot be taken as evidence
against their pathogenicity. This is especially challenging
in the case of such a common cancer as breast cancer,
which affects up to 12% of the population (www.naac-
cr.org). Fortunately, the biallelic presence of pathogenic
BRCA2 alleles is associated with a specific fully penetrant
clinical phenotype known as Fanconi anemia and may
present as microcephalic primordial dwarfism in severe
cases, whereas biallelic BRCA1 mutation is presumably
lethal in humans [21, 22]. Therefore, we hypothesized that
we can challenge at least some of the previously reported
BRCA1 and BRCA2 alleles by demonstrating their pres-
ence in homozygosity in individuals who lack the above-
mentioned phenotype. Indeed, we show that at least 18 of
previously reported VOUS in BRCA1 and BRCA2 can be
questioned as they have also been observed in our data-
base in homozygosity. In addition, we confirm variants
with pathogenic status in BRCA1 and BRCA2 as they
were never encountered in homozygosity except in two
cases with resulting Fanconi anemia phenotype (NM_
000059.3:c.7007G > A:p.Arg2336His and NM_000059.3:
c.9152delC, p.Pro3051Hisfs*11). In view of the highly in-
vasive interventions recommended in patients with patho-
genic BRCA1 or BRCA2 variants, VOUS in these genes
are particularly challenging and we hope our efforts will
help alleviate the anxiety and confusion associated with at
least some of these variants.
Conclusions
We show that the current version of the morbid genome
suffers from specificity limitations and that available
large sequencing initiatives in outbred populations do
not fully address this challenge. The data we present
from the SHGP database provide an example of the
value that population-specific databases add to the ul-
timate goal of constructing a complete and highly spe-
cific map of the human morbid genome.
Methods
Human participants
All sequenced individuals have signed an informed consent
form relevant to the disease with which they presented as
per KFSHRC IRB-approved research protocols. These indi-
viduals were phenotyped for their suspected Mendelian dis-
eases. Venous blood was collected for DNA extraction.
The Saudi Human Genome Program database
The SHGP database is generated on individuals with
various genetic diseases based on the Mendeliome assay
and/or exome sequencing. As described before, the
Mendeliome assay comprises 13 gene panels which
cover the spectrum of “pediatric and adult” clinical gen-
etic medicine [15]. Within each panel, genes were sortedbased on the most prominent sign/symptom with which
they are most likely to be associated upon presentation
to clinical care. A total of 3070 genes covering over 4000
Mendelian disorders as annotated by OMIM up to
August 2013 were used as a basis for the design and syn-
thesis of highly multiplexed gene panels using Ion
AmpliSeq Designer software (Life Technologies,
Carlsbad, CA, USA). For both the Mendeliome assay as
well as for exome sequencing, DNA samples were
treated to obtain Ion Proton AmpliSeq libraries as ap-
propriate. The template-positive Ion PI Ion Sphere parti-
cles were processed for sequencing on the Ion Proton
instrument (Thermo Fisher, Carlsbad, CA, USA).
After running several quality checks as described be-
fore, the reads were aligned using the tmap program
(Ion Torrent Suite, Thermo Fisher, Carlsbad, CA, USA,
https://github.com/iontorrent/TS) to the reference hg19
sequence. The variants within the aligned reads were called
using the Torrent Suite Variant Caller (TVC) program.
A total of 5849 non-overlapping individuals were
assayed using the Mendeliome assay and 2000 were
assayed using whole-exome sequencing as of August
2016. These comprise the content of the SHGP database
until that data.
In addition to these, we sequenced additional 350
exomes from the sample pool using Illumina. That is, we
have 350 samples whose exomes were sequenced using
both the Ion Proton and Illumina platforms. The Illumina
exomes were sequenced as follows: the exome target re-
gions were captured using the TruSeq Exome Enrichment
kit (Illumina) according to the recommended manufac-
turer’s protocol. Then, the individual samples were proc-
essed to produce Illumina sequencing libraries and, in the
subsequent step, the sequencing libraries were enriched
for the desired target using the Illumina Exome Enrich-
ment protocol. The final libraries were then sequenced
using an Illumina HiSeq 2500 Sequencer to an average
read depth of target regions of 81.8X. The reads were
mapped against UCSC hg19 by BWA. The SNVs and
Indels were called using the GATK package.
For both Ion and Illumina exomes, the variants were
annotated using public knowledge databases as well as
in-house variants databases, as described in [15]. The
pathogenicity predictions were computed using SIFT,
PolyPhen2, MutationTaster, MetaSVM, and CADD.
Variant quality
For this study, we used strict quality criteria for includ-
ing the variants to assure correctness of conclusions.
Variants were classified based on the SHGP database in-
formation only if:
1) they are called by both Proton and Illumina
platforms; or
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following criteria: SNP (i.e. not indels) with a
minimum quality score of 1000, depth of 150, and
confirmed by Sanger.
About 99% of the SHGP database variants (in Additional
file 3: Table S3; Additional file 4: Table S4; Additional file 5:
Table S5; Additional file 6: Table S6; Additional file 7:
Table S7; Additional file 8: Table S8; Additional file 9:
Table S9) we report here and contribute to the reclas-
sification outcome are confirmed by both platforms.
In each of the Additional file 3: Table S3; Additional
file 4: Table S4; Additional file 5: Table S5; Additional
file 6: Table S6; Additional file 7: Table S7; Additional
file 8: Table S8; Additional file 9: Table S9, we report
the average quality score and depth for both Ion and
Illumina platforms.
Critical examination of the morbid genome of Mendelian
diseases
We first queried HGMD for all variants with the desig-
nation “disease mutation” (DM), “?disease mutation”
(DM?), “disease-associated polymorphism” (DP), and
“disease-associated polymorphism with supporting func-
tional evidence” (DFP). We also queried ClinVar for all
variants with the designation “VOUS, pathogenic, or
likely pathogenic”. We then examined the frequency of
these variants according to 1000 Genomes, Kaviar, and
ExAC. According to the ACMG guidelines, a population
frequency of > 5% is sufficient to classify a variant as be-
nign [14]. A frequency of < 5% but too high for the ac-
tual disease frequency is insufficient to confidently
classify a variant as benign unless it can also be shown
to be present in an individual who lacks the phenotype
[14]. Since ExAC, Kaviar, and 1000 Genomes are mostly
based on healthy individuals, we classified as benign
dominant alleles with MAF > 0.01 and recessive alleles
with MAF > 0.01 and present homozygous at least once.
We then used our SHGP database to query the same list
of variants and compared the results. To sum up, we
used four criteria to reclassify the variants in HGMD
and ClinVar:
 Criteria 1: reclassification based on allele frequency
larger than or equal to 5% in public databases (1000
Genomes, ExAc, Kaviar).
 Criteria 2: reclassification based on allele frequency
larger than or equal to 5% in the SHGP database
and less than 5% in public databases.
 Criteria 3: reclassification based on allele
frequency larger than or equal to 1% and exists in
at least one homozygous state in the SHGP
database in an individual who lacks the reported
phenotype. Criteria 4: reclassification based on allele frequency
less than 1% and exists at least once in homozygous
state in the SHGP database in an individual who
lacks the reported phenotype.
Because the SHGP database is heavily enriched for in-
dividuals with homozygous pathogenic mutations, we
used the following formula to derive allele frequency
without being biased by the number of diseased
homozygotes: SGPAF ¼ nohet2 noscreened−nohomð Þ
Additionally, we downloaded the entire list of BRCA1
and BRCA2 variants in the BRCA Exchange database
(part of the Global Alliance) that are listed as patho-
genic, likely pathogenic, or VOUS and analyzed them
following the same procedure and criteria described
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